RxDoctor Payments Data

Ajmal Mohammad

Psychiatric/Mental Health · Lawndale, CANPI 1700017712

Payments from drug & device makers

$729in general payments, 2019–2025

Across 33 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$266
  • Vanda Pharmaceuticals Inc.$115
  • Otsuka America Pharmaceutical, Inc.$93
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$73
  • AbbVie$59
  • Indivior Inc.$53
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$68294%
  • Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$729 in reported general payments places this provider in the 60th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$742,692
Medicare patients
1,581
Services billed
9,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega HafyeraPaliperidone Palmitate22$459,119
Invega SustennaPaliperidone Palmitate98$251,629
Invega TrinzaPaliperidone Palmitate23$230,771
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate70$134,118
Aripiprazole OdtAripiprazole64$65,850
Diclofenac Potassium22$35,690
Fenofibrate65$35,646
OrgovyxRelugolix11$30,473
Metformin Er GastricMetformin Hcl66$26,666
RexultiBrexpiprazole15$23,805
JardianceEmpagliflozin29$18,594
LybalviOlanzapine/Samidorphan Malate13$18,220
EliquisApixaban27$15,813
RybelsusSemaglutide13$13,590
Risperidone OdtRisperidone58$13,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$266$482,401121 claims
Otsuka America Pharmaceutical, Inc.Rexulti$93$23,80515 claims
Alkermes, Inc.Lybalvi$15$18,22013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Lawndale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →